Evaluation of vatiquinone drug-drug interaction potential in vitro and in a phase 1 clinical study with tolbutamide, a CYP2C9 substrate, and omeprazole, a CYP2C19 substrate, in healthy subjects
Author:
Funder
PTC Therapeutics
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,General Medicine
Link
https://link.springer.com/content/pdf/10.1007/s00228-022-03393-0.pdf
Reference15 articles.
1. Blankenberg FG, Kinsman SL, Cohen BH et al (2012) Brain uptake of Tc99m-HMPAO correlates with clinical response to the novel redox modulating agent EPI-743 in patients with mitochondrial disease. Mol Genet Metab 107(4):690–699. https://doi.org/10.1016/j.ymgme.2012.09.023
2. Ye L, Stockwell B (2017) Transforming lipoxygenases: PE-specific enzymes in disguise. Cell 171:501–502. https://doi.org/10.1016/j.cell.2017.10.006
3. Joshi YB et al (2015) The 12/15-lipoxygenase as an emerging therapeutic target for Alzheimer’s disease. Trends Pharmacol Sci 36(3):181–186. https://doi.org/10.1016/j.tips.2015.01.005
4. Enns GM et al (2012) Initial experience in the treatment of inherited mitochondrial disease with EPI-743. Mol Genetics Metab 105(1):91–102. https://doi.org/10.1016/j.ymgme.2011.10.009
5. El-Hattab AW et al (2017) Therapies for mitochondrial diseases and current clinical trials. Mol Genetics Metab 122(3):1–9. https://doi.org/10.1016/j.ymgme.2017.09.009
Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Absorption, distribution, metabolism and excretion of 14 C-vatiquinone in rats, dogs, and human subjects;Xenobiotica;2023-05-04
2. Omaveloxolone: an activator of Nrf2 for the treatment of Friedreich ataxia;Expert Opinion on Investigational Drugs;2023-01-02
3. Clinical Drug‐Drug Interaction Between Vatiquinone, a 15‐Lipoxygenase Inhibitor, and Rosuvastatin, a Breast Cancer Resistance Protein Substrate;Clinical Pharmacology in Drug Development;2022-12-07
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3